ロード中...
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
NIHR Journals Library
2010-01-01
|
| シリーズ: | Health Technology Assessment |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.3310/hta14020 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|